Physician profile
Alicia Ann Skibar
NPI 1528244563
$3,698.58
in general payments reported to CMS, 2019-2025
30 companies · $1,343 in 2025
The $1,343 reported for 2025 was more than what 93% of Women'S Health Care, Ambulatory providers received nationally (typical 2025 total: $102).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $304 · 2022: $701 · 2023: $766 · 2024: $584 · 2025: $1,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,693.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $492.49 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $310.79 | 2021-2025 | |
| Axsome Therapeutics, INC. | $249.99 | 2025 | Auvelity |
| Regeneron Healthcare Solutions, INC. | $248.20 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $246.82 | 2025 | Mounjaro, Kisunla |
| Sage Therapeutics, LLC | $203.60 | 2024-2025 | Zurzuvae |
| Regeneron Pharmaceuticals, INC. | $149.98 | 2025 | Dupixent |
| Astellas Pharma US INC | $146.70 | 2023-2024 | Veozah |
| Acella Pharmaceuticals, LLC | $130.01 | 2023 | NP Thyroid 60 |
| Exact Sciences Corporation | $125.75 | 2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $125.00 | 2022 | |
| Lundbeck LLC | $124.99 | 2024 | Vyepti |
| Ucb, INC. | $124.97 | 2024 | Nayzilam |
| Organon LLC | $124.95 | 2021-2025 | Nexplanon |
| Teva Pharmaceuticals USA, INC. | $122.62 | 2023 | Austedo Xr |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $118.46 | 2022 | |
| Gilead Sciences, INC. | $107.22 | 2024 | Epclusa |
| Scynexis, INC. | $101.18 | 2022 | |
| Abbott Laboratories | $100.14 | 2024 | Freestyle Libre 3 |
| Hydrofera LLC | $91.41 | 2023 | Hydrofera Blue |
| Pfizer INC. | $80.34 | 2023-2025 | |
| Exeltis, USA INC. | $41.31 | 2025 | Slynd |
| Supernus Pharmaceuticals, INC. | $26.57 | 2025 | Qelbree |
| Medicem INC. | $20.56 | 2023 | |
| Shield Therapeutics INC | $19.83 | 2025 | |
| Evofem Biosciences, INC. | $16.49 | 2022 | |
| Baxter Healthcare | $16.27 | 2022 | |
| Glaxosmithkline, LLC. | $14.45 | 2025 | Shingrix |
| Therapeuticsmd, INC. | $11.44 | 2021 | |
| Mayne Pharma Commercial LLC | $6.05 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia Skibar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.